Cite
Cui H, Hong Q, Wei R, et al. Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics. Eur J Med Chem. 2021;229:114049doi: 10.1016/j.ejmech.2021.114049.
Cui, H., Hong, Q., Wei, R., Li, H., Wan, C., Chen, X., Zhao, S., Bu, H., Zhang, B., Yang, D., Lu, T., Chen, Y., & Zhu, Y. (2021). Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics. European journal of medicinal chemistry, 229114049. https://doi.org/10.1016/j.ejmech.2021.114049
Cui, Hao, et al. "Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics." European journal of medicinal chemistry vol. 229 (2021): 114049. doi: https://doi.org/10.1016/j.ejmech.2021.114049
Cui H, Hong Q, Wei R, Li H, Wan C, Chen X, Zhao S, Bu H, Zhang B, Yang D, Lu T, Chen Y, Zhu Y. Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics. Eur J Med Chem. 2021 Dec 18;229:114049. doi: 10.1016/j.ejmech.2021.114049. Epub 2021 Dec 18. PMID: 34954594.
Copy
Download .nbib